Inclusion Criteria

Concurrent Medication:

Allowed:

• Approved antiretroviral therapy and/or prophylactic PCP therapy, provided there was no change in such therapy in the 4 weeks prior to study entry.
• Other approved treatments for HIV-related diseases that are not known to affect cellular immune response.
• G-CSF.
• Erythropoietin.
• Supportive care for acute therapy-related toxicity.

Patients must have:

• HIV infection.
• CD4 count 100 - 400 cells/mm3.
• No current or previously documented AIDS-related opportunistic infection, malignancy, or encephalopathy other than mild Kaposi's sarcoma.
• FEV1 > 70 percent, DLCO > 50 percent predicted for height and age (initial infusion only).
• T cell lines with specific cytotoxicity against HIV-1.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Significant autoimmune disease.
• Non-AIDS-associated malignancy.
• Symptoms of cardiac disease.
• Dyspnea on significant exertion.
• Acute infiltrates on chest radiographs.

Patients with the following prior conditions are excluded:

• History of significant arrhythmia, infarction, or heart failure.
• History of a major psychiatric illness.

Prior Medication:

Excluded within 4 weeks prior to study entry:

• Systemic immunosuppressive therapy (i.e., steroids, cyclosporine, chemotherapy, or alpha-interferon).
• Therapy for acute infection, AIDS-related opportunistic infection, or malignancy.
• Experimental AIDS therapy.

Prior Treatment:

Excluded:

• Potentially immunosuppressive local therapy or radiation therapy for Kaposi's sarcoma within 4 weeks prior to study entry.

Current substance abuse.